Emerging Treatment Modalities in Metastatic Breast Cancer: Highlights from SABCS 2022 and Beyond

Komal Jhaveri, MD, FACP, and Paolo Tarantino, MD, discuss updates in the treatment of metastatic breast cancer (mBC) from SABCS 2022 and other recent meetings, and how to best incorporate recent data into clinical practice.

EP. 1: Overview of ER+/HER2- Metastatic Breast Cancer (mBC)

January 30th 2023

Paolo Tarantino, MD, provides an overview of ER-positive, HER2-negative metastatic breast cancer (ER+/HER2- mBC), highlighting the prevalence, patient populations, and the typical prognosis.

EP. 2: Standards of Care in the Frontline Treatment of ER+/HER2- mBC

January 30th 2023

Komal Jhaveri, MD, FACP, explains data on the frontline standard of care treatment approaches for ER-positive HER2-negative mBC.

EP. 3: Use of Second-Generation Oral SERDs in ER+/HER2- mBC

February 7th 2023

Dr Komal Jhaveri highlights important data on oral SERDs for ER-positive HER2-negative mBC that was presented at recent meetings.

EP. 4: The Role of Capivasertib in ER+/HER- mBC

February 13th 2023

Komal Jhaveri, MD, FACP, discusses the role of capivasertib in ER-positive HER2-negative mBC and the design and outcomes of the CAPItello 291 trial.

EP. 5: Standard Practices for the Management of Triple-Negative Breast Cancer (TNBC)

February 22nd 2023

Drs Jhaveri and Tarantino discuss the standard of practice for managing triple negative breast cancer.

EP. 6: The Role of ADCs in the Treatment of TNBC

February 22nd 2023

Dr Jhaveri explains her thoughts on sequencing ADCs in the treatment of triple-negative breast cancer.

EP. 7: Investigational ADCs for Treatment of TNBC

March 2nd 2023

Komal Jhaveri, MD, FACP, explains the potential role ADCs may have in the future of breast cancer treatment.

EP. 8: Emerging Concepts in mBC Treatment

March 2nd 2023

Paolo Tarantino, MD, highlights additional abstracts from SABCS 2022 that he found particularly interesting.